Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Agreement formed for the development of potent siRNA therapeutics in China.

Life Technologies Corporation announces a licensing agreement granting Suzhou Ribo Life Sciences (Ribo) the exclusive rights to develop and manufacture siRNA therapeutics in China using Life's Invivofectamine® Rx delivery technology.  Ribo will formulate proprietary siRNA molecules in combination with Invivofectamine® Rx to create a new platform designed to address human diseases with high unmet medical need in the Chinese healthcare system.

Under the agreement, Ribo will receive a license to develop a robust pipeline of Invivofectamine® Rx-based therapeutics, for each of which Life Technologies is entitled to receive milestone and royalty payments.

Currently available only through Life Technologies' out-licensing program (outlicensing@lifetech.com), Invivofectamine Rx marks a significant advancement in the company's in vivo transfection product line. The novel formulation uses a proprietary chemical structure to dramatically increase the potency 100-fold and decrease the toxicity of the formulated RNAi compound. The increased therapeutic window makes the solution particularly well-suited for use in in vivo applications.

"We are extremely pleased to announce this partnership with Life Technologies," said Zicai Liang, Ph.D., chief executive officer and founder of Ribo and the Kunshan RNAi Institute. "Adding Life's Invivofectamine Rx formulation technology into our development efforts will significantly increase our ability to bring new siRNA therapeutics to Chinese patients with unmet medical needs. We look forward to bringing our first Invivofectamine Rx-based program targeting Hepatitis-B into the clinic in a relatively short period of time."

The Chinese government has identified siRNA therapeutics as one of the few critical emerging technologies in which it wants to have a dominant presence. To help meet this objective, the government is nearing completion on the construction of a new, 400,000-square-foot, state-of-the-art facility in Kunshan, China for Ribo Life Sciences and the Kunshan Institute of siRNA.

"Dr. Liang is a premier siRNA expert in China and his Kunshan RNAi Institute is recognized as one of the world's leading consortiums of academic, industry and government efforts in the world to advance siRNA technology," said Alan Sachs, M.D., Ph.D., chief scientific officer and head of global research at Life Technologies. "In our continued effort to deliver game-changing products and technologies to the world's top medical researchers, we are pleased to partner with Dr. Liang and Suzhou Ribo Life Sciences. Invivofectamine Rx is a great example of the type of technology we will continue to license around the world as we expand our commitment to clinical research customers."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Announces First Quarter 2013 Results
Revenue increased 2.5% to $963 million.
Friday, May 03, 2013
Life Technologies Establishes International Influenza Network
Scientists at leading public health agencies and research institutes collaborate to develop faster, more reliable flu subtyping methods.
Friday, February 01, 2013
Life Technologies Acquires BAC BV
The acquisition expands Life Technologies capabilities and product offerings in biopharmaceutical research and manufacturing.
Tuesday, January 22, 2013
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!